1. Home
  2. NEWS
  3. FDA Grants Orphan Drug Designation to Revolutionary Cystic Fibrosis Therapy

FDA Grants Orphan Drug Designation to Revolutionary Cystic Fibrosis Therapy

FDA Grants Orphan Drug Designation to Revolutionary Cystic Fibrosis Therapy

Porosome Therapeutics, Inc. enters a new frontier in secretory defect therapeutics through porosome reconstitution

BOSTON--()--Porosome Therapeutics, Inc. (Porosome Therapeutics) today announced the Orphan Drug Designation of its cystic fibrosis therapy by the Food and Drug Administration (FDA).

https://www.businesswire.com/news/home/20250225004448/en/FDA-Grants-Orphan-Drug-Designation-to-Revolutionary-Cystic-Fibrosis-Therapy

Porosome Therapeutics, Inc. Academic Chairman Prof. Bhanu P. Jena to present Keynote Lecture entitled: “The Porosome Secretory Nanomachine: Discovery to Therapy”, at the International Drug Discovery Science & Technology (IDDST) Congress in Kyoto, Japan
State of Science at Porosome Therapeutics, Inc.
Porosome reconstitution therapy: A biologic rescue from cystic fibrosis (In human lung organoids and in CF mice)